Currently Viewing:
Newsroom
Currently Reading
What We're Reading: UnitedHealthcare Prefers Biosimilars; Migraine Coverage; Prostate Cancer Disparity
October 18, 2018 – AJMC Staff
Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial
October 17, 2018 – Samantha DiGrande
Implantable Device for Chronic Pain Reduced Disability Scores by 27%
October 17, 2018 – Allison Inserro
Express Scripts Launching Value-Based Migraine Program
October 17, 2018 – Jaime Rosenberg
Dupilumab Shows Positive Results for Chronic Rhinosinusitis With Nasal Polyps
October 17, 2018 – Allison Inserro
What We're Reading: Promoting Pediatric Cancer Research; Mystery Paralysis; Cost of Being Sick
October 17, 2018 – AJMC Staff
Value-Based Payment Success Hinges on a Holistic Strategy for Changes
October 17, 2018 – Laura Joszt
Trial Will Examine Novel HIV Vaccine Candidate Designed to Stimulate Immune Response
October 16, 2018 – Jaime Rosenberg
FDA Label Rule Change Gives Prescribers More Detail for Pregnant Women With Asthma
October 16, 2018 – David Bai

What We're Reading: Short-Term Plan Vote; Support for Rituxan Biosimilar; Centene Expands ACA Footprint

AJMC Staff
Senate Democrats were 1 vote short of overturning the Trump administration's expansion of short-term health plans; Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel; Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019.

Senate Democrats Vote on Short-Term Insurance Plans

Democrats forced a vote on the Trump administration’s expansion of short-term health insurance plans that do not have to comply with Affordable Care Act (ACA) regulations. However, they fell short of overturning the expansion of these plans by just 1 vote, according to The Washington Post. Democrats voted unanimously to overturn the administration rule and also brought in a vote from Senator Susan Collins, R-Maine, but they would have needed a second Republican vote in order to pass the legislation. In addition, President Donald Trump had already threatened to veto the measure if it reached his desk.

 

FDA Panel Votes in Favor of Rituxan Biosimilar

Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel. Reuters reported that the panel ruled Celltrion’s biosimilar was highly similar to the reference biologic. In February, the FDA had declined to approve the proposed biosimilar, citing a manufacturing issue. The FDA usually follows the advice of its advisory panels.

 

Centene Will Expand ACA Footprint

As more insurers are able to find profits in the ACA marketplaces, they have been expanding their participation. Insurer Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019, according to Fierce Healthcare. The company had increased revenue 13% at the end of the first quarter in 2018. In June, Molina Healthcare and Oscar Insurance reported they were entering new states.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!